Tag : OBERON

CONFERENCE UPDATE

Tozorakimab significantly reduces COPD exacerbations across a broad patient population: The phase 3 OBERON and TITANIA studies
OBERON and TITANIA demonstrated that tozorakimab significantly reduced the annualized rate of moderate/severe exacerbations vs. placebo in patients with COPD and a history of exacerbations. The benefit was consistently observed across smoking status, airflow obstruction, and BEC subgroups, with a safety profile generally similar to placebo, apart from a higher incidence of injection-site reactions.